Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Completes patient enrolment for bridging phase two study in China to evaluate the efficacy of cancer drug Tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma. Tazemetostat is approved by the US Food & Drug Administration for the treatment of advanced epithelioid sarcoma and R/R FL. Current stock price: 237.29 pence, down 1.3% on Tuesday 12-month change: down 1.1% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|